Successful Treatment with Afatinib after Osimertinib-induced Interstitial Lung Disease in a Patient with EGFR-mutant Non-small-cell Lung Cancer

Osimertinib is the standard treatment for epidermal growth factor receptor (EGFR)-mutant non-small-cell lung cancer. However, drug-induced interstitial lung disease (ILD) is recognized as a serious adverse event associated with EGFR-tyrosine kinase inhibitors (TKIs). We herein report a 78-year-old w...

תיאור מלא

שמור ב:
מידע ביבליוגרפי
הוצא לאור ב:Intern Med
Main Authors: Nishima, Shunichi, Miyanaga, Akihiko, Saito, Sho, Yuasa, Mizuki, Takahashi, Satoshi, Kashiwada, Takeru, Sugano, Teppei, Noro, Rintaro, Minegishi, Yuji, Terasaki, Yasuhiro, Saito, Yoshinobu, Kubota, Kaoru, Seike, Masahiro, Gemma, Akihiko
פורמט: Artigo
שפה:Inglês
יצא לאור: The Japanese Society of Internal Medicine 2020
נושאים:
Case Report
גישה מקוונת:https://ncbi.nlm.nih.gov/pmc/articles/PMC7946498/
https://ncbi.nlm.nih.gov/pubmed/32999231
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2169/internalmedicine.5435-20
תגים: הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!

פריטים דומים